2 active not recruiting, 1 recruiting, 1 terminated. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 2, Recruiting 1, Terminated 1 |
| Phase 2 | 3 | Active not recruiting 2, Terminated 1 |
Follow Ocugen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME) OCU200 - Center Involved Diabetic Macular Edema, Diabetic Macular Edema | Phase 1 | Recruiting | Ocugen | 24 | 2024-01-13 | 2026-07-31 |
| Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy OCU410 - Geographic Atrophy | Phase 1 / Phase 2 | Active not recruiting | Ocugen | 60 | 2023-02-23 | 2026-10-30 |
| Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose - Retinitis Pigmentosa, Leber Congenital Amaurosis | Phase 1 / Phase 2 | Active not recruiting | Ocugen | 22 | 2022-01-24 | 2026-07-31 |
| Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD) Brimonidine 0.15%, Brimonidine 0.075%, Placebo - Dry Eye, Ocular Graft vs Host Disease | Phase 1 / Phase 2 | Terminated | Sandeep Jain, MD | 15 | 2016-05-01 | 2019-11-08 |
Dry Eye Syndromes (1) · Enhanced S-Cone Syndrome (1) · Geographic Atrophy (1) · Leber Congenital Amaurosis (1) · Meckel Syndrome, Type 4 (1) · Meibomian Gland Dysfunction (1) · Night Blindness, Congenital Stationary, Autosomal Dominant 1 (1) · Retinitis Pigmentosa (1)
Brimonidine Tartrate (1) · Lubricant Eye Drops (1)
United States (4)
Jennifer Henrick, RN, MS (3) · Mohamed Genead, MD (3) · Sandeep Jain, MD (1)